Silver Book Fact

For beneficiaries with wet age-related macular degeneration (AMD), annual Medicare part B payments for vision care increased from $1,504 per beneficiary in 1994 to $3,263 in 2006–due in large part to anti-VEGF treatments.

Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. Ophthalmol. May 2011; 152(6): 1014-20. http://www.ajo.com/article/S0002-9394%2811%2900410-7/abstract

Reference

Title
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007
Publication
Ophthalmol
Publication Date
May 2011
Authors
Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan
Volume & Issue
Volume 152, Issue 6
Pages
1014-20
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Visual loss from subfoveal choroidal neovascularization, a characteristic of wet age-related macular degeneration (AMD), was found to have a profound impact on how patients felt about their health-related quality of…  
  • More than 7.6 million Americans age 40 and older have diabetic retinopathy—7,685,237.  
  • Low vision or blindness affects 1 in 28 Americans over the age of 40– 3.3 million Americans.  
  • Up to 80% of diabetics who have had the disease for 10 years or more are affected by diabetic retinopathy.  
  • From 2005 – 2008, around 4.2 million diabetics age 40 and older had diabetic retinopathy.  Of these, 655,000 had advanced diabetic retinopathy that could lead to severe vision loss.